The Impact of Antispasmodic Use on Abdominal Pain and Opioid Use in Inflammatory Bowel Disease: A Population‐Based Study
Alimentary Pharmacology & Therapeutics · 2025
DOI: 10.1111/apt.70147 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2025. Verfasst von Chachrit Khunsriraksakul und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Johns Hopkins Hospital, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Analgesics, Opioid, Abdominal Pain, Inflammatory Bowel Diseases, Parasympatholytics. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NLM NIH HHS, NIDDK NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Background
Patients with inflammatory bowel disease (IBD) are often prescribed antispasmodics for chronic abdominal pain. Large‐scale data regarding efficacy and impact on clinical outcomes are lacking.
Aim
To examine the association between antispasmodic use and outcomes of abdominal pain and opioid use before and after propensity matching key demographic and clinical characteristics.
Methods
We used TriNetX Diamond Network, a medical and claims database. Patients were stratified by baseline abdominal pain and opioid use. Secondary outcomes were corticosteroid use, IBD‐related complications and surgeries, emergency room (ER) visits, hospitalisation and mortality.
Results
We included 85,859 patients (median age 50; 53.8% female) with IBD; 5661 used antispasmodics. On follow‐up, those with antispasmodic use had higher rates of abdominal pain and opioid use ( p < 0.001) regardless of baseline abdominal pain or opioid use. After matching, 5629 patients remained per group. Patients who used antispasmodics had higher rates of abdominal pain at 1 month, regardless of baseline abdominal pain. Opioid‐naïve patients who used antispasmodics had higher rates of opioid use at follow‐up (1.1% vs. 0.2%; p < 0.001). The likelihood of corticosteroid use, clinic visits, ER visits and hospitalisation were higher in those with antispasmodic use. No differences in IBD‐related complications, surgery or mortality were observed.
Conclusions
Antispasmodic use in patients with IBD was associated with increased abdominal pain and opioid use in opioid‐naïve patients. Antispasmodic use was associated with increased likelihood of corticosteroid use, clinic and ER visits and hospitalisation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Johns Hopkins Hospital, Baltimore, Maryland, USA.
- Medical Scientist Training Program, Penn State College of Medicine, Hershey, Pennsylvania, USA.
- Department of General Surgery, Penn State College of Medicine, Hershey, Pennsylvania, USA.
- Department of Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania, USA.
- Division of Colon and Rectal Surgery, Penn State College of Medicine, Hershey, Pennsylvania, USA.
- Division of Gastroenterology and Hepatology, Penn State College of Medicine, Hershey, Pennsylvania, USA.
ORCID-Profile: Olivia Ziegler, Matthew D Coates
Förderung
- NLM NIH HHS
- NIDDK NIH HHS
- NIGMS NIH HHS
- NIH HHS
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Khunsriraksakul, C., Ziegler, O., Liu, D., Kulaylat, A. S., & Coates, M. D. (2025). The Impact of Antispasmodic Use on Abdominal Pain and Opioid Use in Inflammatory Bowel Disease: A Population‐Based Study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70147
Vancouver
Khunsriraksakul C, Ziegler O, Liu D, Kulaylat AS, Coates MD. The Impact of Antispasmodic Use on Abdominal Pain and Opioid Use in Inflammatory Bowel Disease: A Population‐Based Study. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70147
BibTeX
@article{Khunsriraksakul2025,
author = {Khunsriraksakul, Chachrit and Ziegler, Olivia and Liu, Dajiang and Kulaylat, Audrey S and Coates, Matthew D},
title = {The Impact of Antispasmodic Use on Abdominal Pain and Opioid Use in Inflammatory Bowel Disease: A Population‐Based Study},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
doi = {10.1111/apt.70147}
}
EUVIMED